{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:49:04Z","timestamp":1790815744577,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases,United States","award":["AI180532"],"award-info":[{"award-number":["AI180532"]}]},{"name":"National Institute of Allergy and Infectious Diseases,United States","award":["AI125704"],"award-info":[{"award-number":["AI125704"]}]},{"name":"National Institute of Allergy and Infectious Diseases,United States","award":["AI125704"],"award-info":[{"award-number":["AI125704"]}]},{"name":"National Institute of Allergy and Infectious Diseases,United States","award":["AI125704"],"award-info":[{"award-number":["AI125704"]}]},{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-22-1-0029"],"award-info":[{"award-number":["HDTRA1-22-1-0029"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-22-1-0029"],"award-info":[{"award-number":["HDTRA1-22-1-0029"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-22-1-0029"],"award-info":[{"award-number":["HDTRA1-22-1-0029"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-22-1-0029"],"award-info":[{"award-number":["HDTRA1-22-1-0029"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI093504"],"award-info":[{"award-number":["AI093504"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI093504"],"award-info":[{"award-number":["AI093504"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI093504"],"award-info":[{"award-number":["AI093504"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Botulinum neurotoxins (BoNTs) are the most potent toxins known, causing life-threatening flaccid paralysis by blocking acetylcholine release at neuromuscular junctions. Clinical botulism results in respiratory failure, requiring prolonged artificial ventilation for survival. The only specific therapy is antitoxin, which neutralizes circulating toxin but cannot affect toxin within neurons, resulting in a narrow therapeutic window. Due to its high potency and lack of treatment options, large-scale BoNT exposures present profound risks to human life. Thus, there is an urgent need for rapidly acting symptomatic therapies that can reverse respiratory paralysis and sustain survival until resolution of toxin effects. We previously identified the FDA-approved, voltage-gated potassium channel blocker 3,4-diaminopyridine (3,4-DAP) as a fast-acting symptomatic treatment in preclinical botulism models. Here, we expand upon those findings by evaluating continuous infusion of 3,4-DAP in rats exposed to a typical range of BoNT\/A doses. Infusion of clinically relevant doses of 3,4-DAP improved survival, reversed respiratory paralysis, and rapidly alleviated clinical signs at toxin doses substantially higher than previously studied. Therapeutic efficacy of 3,4-DAP correlated inversely with toxin exposure, consistent with its proposed mechanism of enhancing acetylcholine release from residual functional synaptic vesicle pools. 3,4-DAP treatment remained effective even when initiated at advanced stages of botulism, when antitoxin monotherapy provided no benefit, significantly extending the clinical treatment window. Combining 3,4-DAP infusion with antitoxin had robust effects on clinical outcomes, reversing clinical symptoms and improving survival compared to either treatment alone. Monitoring of body temperature further revealed that significant hypothermia precedes overt clinical symptoms, providing a novel biomarker of intoxication and treatment efficacy, as toxin-induced hypothermia resolved within hours after 3,4-DAP administration. Collectively, these findings provide robust preclinical evidence supporting clinical translation of 3,4-DAP as a symptomatic reversal agent for botulism, potentially transforming clinical management strategies for this lethal neurotoxin-induced disease.<\/jats:p>","DOI":"10.1186\/s10020-025-01316-0","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T19:23:16Z","timestamp":1753730596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Combined treatment with antitoxin and 3,4-diaminopyridine improves survival outcomes after lethal botulinum neurotoxin challenge"],"prefix":"10.1186","volume":"31","author":[{"given":"Sean W.","family":"O\u2019Brien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brieana M.","family":"Gregg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adhirath","family":"Bollapragada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"McNutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"1316_CR1","doi-asserted-by":"publisher","first-page":"e0224700","DOI":"10.1371\/journal.pone.0224700","volume":"14","author":"DM Anderson","year":"2019","unstructured":"Anderson DM, Kumar VR, Arper DL, Kruger E, Bilir SP, Richardson JS. Cost savings associated with timely treatment of botulism with botulism antitoxin heptavalent product. PLoS One. 2019;14:e0224700. https:\/\/doi.org\/10.1371\/journal.pone.0224700.","journal-title":"PLoS One"},{"key":"1316_CR2","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1056\/NEJMoa051926","volume":"354","author":"SS Arnon","year":"2006","unstructured":"Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006;354:462\u201371. https:\/\/doi.org\/10.1056\/NEJMoa051926.","journal-title":"N Engl J Med"},{"key":"1316_CR3","volume-title":"Use of 4-aminopyridine in human botulismpergamon","author":"AP Ball","year":"1982","unstructured":"Ball AP, Snow M, Paul R. Use of 4-aminopyridine in human botulismpergamon. 1982."},{"key":"1316_CR4","doi-asserted-by":"publisher","first-page":"15862","DOI":"10.1038\/s41598-017-16064-3","volume":"7","author":"PH Beske","year":"2017","unstructured":"Beske PH, Hoffman KM, Machamer JB, Eisen MR, McNutt PM. Use-dependent potentiation of voltage-gated calcium channels rescues neurotransmission in nerve terminals intoxicated by botulinum neurotoxin serotype A. Sci Rep. 2017;7:15862. https:\/\/doi.org\/10.1038\/s41598-017-16064-3.","journal-title":"Sci Rep"},{"key":"1316_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.toxicon.2017.10.017","volume":"147","author":"PH Beske","year":"2018","unstructured":"Beske PH, Bradford AB, Hoffman KM, Mason SJ, McNutt PM. In vitro and ex vivo screening of candidate therapeutics to restore neurotransmission in nerve terminals intoxicated by botulinum neurotoxin serotype A1. Toxicon. 2018;147:47\u201353. https:\/\/doi.org\/10.1016\/j.toxicon.2017.10.017.","journal-title":"Toxicon"},{"key":"1316_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.taap.2018.01.012","volume":"341","author":"AB Bradford","year":"2018","unstructured":"Bradford AB, Machamer JB, Russo TM, McNutt PM. 3,4-diaminopyridine reverses paralysis in botulinum neurotoxin-intoxicated diaphragms through two functionally distinct mechanisms. Toxicol Appl Pharmacol. 2018;341:77\u201386. https:\/\/doi.org\/10.1016\/j.taap.2018.01.012.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1316_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1113\/jphysiol.1949.sp004364","volume":"109","author":"AS Burgen","year":"1949","unstructured":"Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949;109:10\u201324. https:\/\/doi.org\/10.1113\/jphysiol.1949.sp004364.","journal-title":"J Physiol"},{"key":"1316_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/DMP.0b013e318158c5fd","volume":"1","author":"ZF Dembek","year":"2007","unstructured":"Dembek ZF, Smith LA, Rusnak JM. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep. 2007;1:122\u201334. https:\/\/doi.org\/10.1097\/DMP.0b013e318158c5fd.","journal-title":"Disaster Med Public Health Prep"},{"key":"1316_CR9","first-page":"601","volume":"31","author":"M Dock","year":"2002","unstructured":"Dock M, Ben Ali A, Karras A, Misset B, Garrouste-Orgeas M, Deletie E, Goldstein F, Carlet J. Treatment of severe botulism with 3,4-diaminopyridine. Presse Med. 2002;31:601\u20132.","journal-title":"Presse Med"},{"key":"1316_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/cc12880","volume":"17","author":"A Friggeri","year":"2013","unstructured":"Friggeri A, Marcon F, Marciniak S, Lemaire-Hurtel AS, Seydi A, Ammenouche N, Levrard M, Mahjoub Y, Airapetian N, Tinturier F, et al. 3,4-Diaminopyridine may improve neuromuscular block during botulism. Crit Care. 2013;17:449. https:\/\/doi.org\/10.1186\/cc12880.","journal-title":"Crit Care"},{"key":"1316_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1558944721994250","volume":"18","author":"SH Goldberg","year":"2023","unstructured":"Goldberg SH, Gehrman MD, Graham JH. Botulinum toxin a and b improve perfusion, increase flap survival, cause vasodilation, and prevent thrombosis: a systematic review and meta-analysis of controlled animal studies. Hand (n y). 2023;18:22\u201331. https:\/\/doi.org\/10.1177\/1558944721994250.","journal-title":"Hand (n y)"},{"key":"1316_CR12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/0031-9384(90)90025-y","volume":"47","author":"CJ Gordon","year":"1990","unstructured":"Gordon CJ. Thermal biology of the laboratory rat. Physiol Behav. 1990;47:963\u201391. https:\/\/doi.org\/10.1016\/0031-9384(90)90025-y.","journal-title":"Physiol Behav"},{"key":"1316_CR13","doi-asserted-by":"publisher","first-page":"e0154141","DOI":"10.1371\/journal.pone.0154141","volume":"11","author":"EM Granjeiro","year":"2016","unstructured":"Granjeiro EM, da Silva GS, Giusti H, Oliveira JA, Glass ML, Garcia-Cairasco N. Behavioral, ventilatory and thermoregulatory responses to hypercapnia and hypoxia in the Wistar Audiogenic Rat (WAR) strain. PLoS One. 2016;11:e0154141. https:\/\/doi.org\/10.1371\/journal.pone.0154141.","journal-title":"PLoS One"},{"key":"1316_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/s0959-4388(97)80057-8","volume":"7","author":"PI Hanson","year":"1997","unstructured":"Hanson PI, Heuser JE, Jahn R. Neurotransmitter release - four years of SNARE complexes. Curr Opin Neurobiol. 1997;7:310\u20135. https:\/\/doi.org\/10.1016\/s0959-4388(97)80057-8.","journal-title":"Curr Opin Neurobiol"},{"key":"1316_CR15","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1002\/j.1460-2075.1994.tb06834.x","volume":"13","author":"T Hayashi","year":"1994","unstructured":"Hayashi T, McMahon H, Yamasaki S, Binz T, Hata Y, Sudhof TC, Niemann H. Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly. EMBO J. 1994;13:5051\u201361. https:\/\/doi.org\/10.1002\/j.1460-2075.1994.tb06834.x.","journal-title":"EMBO J"},{"key":"1316_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bmt.2024.06.003","volume":"7","author":"P He","year":"2024","unstructured":"He P, Yan R, Liu J, You P, Zhang J, Li J, Zhang Y. The therapeutic efficacy of post-symptom 3,4-diaminopyridine treatment in cosmetic injection-induced botulism using a novel animal model. Biomed Technol. 2024;7:25\u201331.","journal-title":"Biomedical Technology"},{"key":"1316_CR17","doi-asserted-by":"publisher","unstructured":"Ishida N, Kondo Y, Chikano Y, Kobayashi-Nakade E, Suga Y, Ishizaki J, Komai K, Matsushita R. Pharmacokinetics and Tissue Distribution of 3,4-Diaminopyridine in rats. Biopharm Drug Dispos.\u00a02019. https:\/\/doi.org\/10.1002\/bdd.2203.","DOI":"10.1002\/bdd.2203"},{"key":"1316_CR18","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.str.2017.09.004","volume":"25","author":"R Khounlo","year":"2017","unstructured":"Khounlo R, Kim J, Yin L, Shin YK. Botulinum toxins A and E inflict dynamic destabilization on t-SNARE to impair SNARE assembly and membrane fusion. Structure. 2017;25:1679-1686.e1675. https:\/\/doi.org\/10.1016\/j.str.2017.09.004.","journal-title":"Structure"},{"key":"1316_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0006-3495(78)85503-9","volume":"22","author":"GE Kirsch","year":"1978","unstructured":"Kirsch GE, Narahashi T. 3,4-diaminopyridine. A potent new potassium channel blocker. Biophys J. 1978;22:507\u201312. https:\/\/doi.org\/10.1016\/S0006-3495(78)85503-9.","journal-title":"Biophys J"},{"key":"1316_CR20","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1152\/jn.00168.2017","volume":"119","author":"R Laghaei","year":"2018","unstructured":"Laghaei R, Ma J, Tarr TB, Homan AE, Kelly L, Tilvawala MS, Vuocolo BS, Rajasekaran HP, Meriney SD, Dittrich M. Transmitter release site organization can predict synaptic function at the neuromuscular junction. J Neurophysiol. 2018;119:1340\u201355. https:\/\/doi.org\/10.1152\/jn.00168.2017.","journal-title":"J Neurophysiol"},{"key":"1316_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1128\/CMR.19.2.298-314.2006","volume":"19","author":"M Lindstrom","year":"2006","unstructured":"Lindstrom M, Korkeala H. Laboratory diagnostics of botulism. Clin Microbiol Rev. 2006;19:298\u2013314. https:\/\/doi.org\/10.1128\/CMR.19.2.298-314.2006.","journal-title":"Clin Microbiol Rev"},{"key":"1316_CR22","doi-asserted-by":"publisher","first-page":"e1065","DOI":"10.7717\/peerj.1065","volume":"3","author":"B Lu","year":"2015","unstructured":"Lu B. The destructive effect of botulinum neurotoxins on the SNARE protein: SNAP-25 and synaptic membrane fusion. PeerJ. 2015;3:e1065. https:\/\/doi.org\/10.7717\/peerj.1065.","journal-title":"PeerJ"},{"key":"1316_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10020-022-00487-4","volume":"28","author":"JB Machamer","year":"2022","unstructured":"Machamer JB, Vazquez-Cintron EJ, O\u2019Brien SW, Kelly KE, Altvater AC, Pagarigan KT, Dubee PB, Ondeck CA, McNutt PM. Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine. Mol Med. 2022;28:61. https:\/\/doi.org\/10.1186\/s10020-022-00487-4.","journal-title":"Mol Med"},{"key":"1316_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1124\/jpet.123.001773","volume":"388","author":"WT McClintic","year":"2024","unstructured":"McClintic WT, Chandler ZD, Karchalla LM, Ondeck CA, O\u2019Brien SW, Campbell CJ, Jacobson AR, McNutt PM. Aminopyridines restore ventilation and reverse respiratory acidosis at late stages of botulism in mice. J Pharmacol Exp Ther. 2024;388:637\u201346. https:\/\/doi.org\/10.1124\/jpet.123.001773.","journal-title":"J Pharmacol Exp Ther"},{"key":"1316_CR25","doi-asserted-by":"publisher","unstructured":"McNutt PM, Vazquez-Cintron EJ, Tenezaca L, Ondeck CA, Kelly KE, Mangkhalakhili M, Machamer JB, Angeles CA, Glotfelty EJ, Cika J, et al. Neuronal delivery of antibodies has therapeutic effects in animal models of botulism. Sci Transl Med.\u00a02021;13. https:\/\/doi.org\/10.1126\/scitranslmed.abd7789.","DOI":"10.1126\/scitranslmed.abd7789"},{"key":"1316_CR26","doi-asserted-by":"publisher","unstructured":"Miyashita SI, Zhang J, Zhang S, Shoemaker CB, Dong M. Delivery of single-domain antibodies into neurons using a chimeric toxin-based platform is therapeutic in mouse models of botulism. Sci Transl Med.\u00a02021;13. https:\/\/doi.org\/10.1126\/scitranslmed.aaz4197.","DOI":"10.1126\/scitranslmed.aaz4197"},{"key":"1316_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.toxicon.2008.11.018","volume":"54","author":"M Montal","year":"2009","unstructured":"Montal M. Translocation of botulinum neurotoxin light chain protease by the heavy chain protein-conducting channel. Toxicon. 2009;54:565\u20139. https:\/\/doi.org\/10.1016\/j.toxicon.2008.11.018.","journal-title":"Toxicon"},{"key":"1316_CR28","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/toxins4121565","volume":"4","author":"J Mukherjee","year":"2012","unstructured":"Mukherjee J, McCann C, Ofori K, Hill J, Baldwin K, Shoemaker CB, Harrison P, Tzipori S. Sheep monoclonal antibodies prevent systemic effects of botulinum neurotoxin A1. Toxins (Basel). 2012;4:1565\u201381. https:\/\/doi.org\/10.3390\/toxins4121565.","journal-title":"Toxins (Basel)"},{"key":"1316_CR29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/mus.25208","volume":"55","author":"F Ng","year":"2017","unstructured":"Ng F, Lee DC, Schrumpf LA, Mazurek ME, Lee Lo V, Gill SK, Maselli RA. Effect of 3,4-diaminopyridine at the murine neuromuscular junction. Muscle Nerve. 2017;55:223\u201331. https:\/\/doi.org\/10.1002\/mus.25208.","journal-title":"Muscle Nerve"},{"key":"1316_CR30","doi-asserted-by":"publisher","first-page":"100302","DOI":"10.1016\/j.jbc.2021.100302","volume":"296","author":"KS Ojala","year":"2021","unstructured":"Ojala KS, Ginebaugh SP, Wu M, Miller EW, Ortiz G, Covarrubias M, Meriney SD. A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs. J Biol Chem. 2021;296:100302. https:\/\/doi.org\/10.1016\/j.jbc.2021.100302.","journal-title":"J Biol Chem"},{"key":"1316_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1124\/pr.116.012658","volume":"69","author":"M Pirazzini","year":"2017","unstructured":"Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69:200\u201335. https:\/\/doi.org\/10.1124\/pr.116.012658.","journal-title":"Pharmacol Rev"},{"key":"1316_CR32","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/1799","volume":"5","author":"MA Poirier","year":"1998","unstructured":"Poirier MA, Xiao W, Macosko JC, Chan C, Shin YK, Bennett MK. The synaptic SNARE complex is a parallel four-stranded helical bundle. Nat Struct Biol. 1998;5:765\u20139. https:\/\/doi.org\/10.1038\/1799.","journal-title":"Nat Struct Biol"},{"key":"1316_CR33","doi-asserted-by":"publisher","unstructured":"Richardson JS, Parrera GS, Astacio H, Sahota H, Anderson DM, Hall C, Babinchak T. Safety and clinical outcomes of an equine-derived heptavalent botulinum antitoxin treatment for confirmed or suspected botulism in the United States. Clin Infect Dis. 2019. https:\/\/doi.org\/10.1093\/cid\/ciz515.","DOI":"10.1093\/cid\/ciz515"},{"key":"1316_CR34","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1523\/JNEUROSCI.4663-10.2011","volume":"31","author":"R Ruiz","year":"2011","unstructured":"Ruiz R, Cano R, Casanas JJ, Gaffield MA, Betz WJ, Tabares L. Active zones and the readily releasable pool of synaptic vesicles at the neuromuscular junction of the mouse. J Neurosci. 2011;31:2000\u20138. https:\/\/doi.org\/10.1523\/JNEUROSCI.4663-10.2011.","journal-title":"J Neurosci"},{"key":"1316_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev.pharmtox.44.101802.121554","volume":"44","author":"LL Simpson","year":"2004","unstructured":"Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol. 2004;44:167\u201393.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1316_CR36","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1086\/444507","volume":"41","author":"J Sobel","year":"2005","unstructured":"Sobel J. Botulism. Clin Infect Dis. 2005;41:1167\u201373. https:\/\/doi.org\/10.1086\/444507.","journal-title":"Clin Infect Dis"},{"key":"1316_CR37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000336354","volume":"38","author":"N Souayah","year":"2012","unstructured":"Souayah N, Mehyar LS, Khan HM, Yacoub HA, Abed Al-Kariem AA-QZ, Nasar A, Sheikh ZB, Maybodi L, Qureshi AI. Trends in outcome and hospitalization charges of adult patients admitted with botulism in the United States. Neuroepidemiology. 2012;38:233\u20136. https:\/\/doi.org\/10.1159\/000336354.","journal-title":"Neuroepidemiology"},{"key":"1316_CR38","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/26412","volume":"395","author":"RB Sutton","year":"1998","unstructured":"Sutton RB, Fasshauer D, Jahn R, Brunger AT. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature. 1998;395:347\u201353. https:\/\/doi.org\/10.1038\/26412.","journal-title":"Nature"},{"key":"1316_CR39","doi-asserted-by":"publisher","first-page":"10559","DOI":"10.1523\/JNEUROSCI.4629-12.2013","volume":"33","author":"TB Tarr","year":"2013","unstructured":"Tarr TB, Malick W, Liang M, Valdomir G, Frasso M, Lacomis D, Reddel SW, Garcia-Ocano A, Wipf P, Meriney SD. Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. J Neurosci. 2013;33:10559\u201367. https:\/\/doi.org\/10.1523\/JNEUROSCI.4629-12.2013.","journal-title":"J Neurosci"},{"key":"1316_CR40","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/psp4.12218","volume":"6","author":"N Thakkar","year":"2017","unstructured":"Thakkar N, Guptill JT, Ales K, Jacobus D, Jacobus L, Peloquin C, Cohen-Wolkowiez M, Gonzalez D, Group DS. Population pharmacokinetics\/pharmacodynamics of 3,4-diaminopyridine free base in patients with lambert-eaton myasthenia. CPT Pharmacometrics Syst Pharmacol. 2017;6:625\u201334. https:\/\/doi.org\/10.1002\/psp4.12218.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1316_CR41","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0022-3565(25)22023-7","volume":"227","author":"RH Thomsen","year":"1983","unstructured":"Thomsen RH, Wilson DF. Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J Pharmacol Exp Ther. 1983;227:260\u20135.","journal-title":"J Pharmacol Exp Ther"},{"key":"1316_CR42","doi-asserted-by":"publisher","unstructured":"Tremblay JM, Vazquez-Cintron E, Lam KH, Mukherjee J, Bedenice D, Ondeck CA, Conroy MT, Bodt SML, Winner BM, Webb RP, et al. Camelid VHH Antibodies that Neutralize Botulinum Neurotoxin Serotype E Intoxication or Protease Function. Toxins (Basel). 2020;12. https:\/\/doi.org\/10.3390\/toxins12100611.","DOI":"10.3390\/toxins12100611"},{"key":"1316_CR43","doi-asserted-by":"publisher","unstructured":"Vazquez-Cintron E, Machamer J, Ondeck C, Pagarigan K, Winner B, Bodner P, Kelly K, Pennington MR, McNutt P. Symptomatic treatment of botulism with a clinically approved small molecule. JCI Insight.\u00a02020;5. https:\/\/doi.org\/10.1172\/jci.insight.132891.","DOI":"10.1172\/jci.insight.132891"},{"key":"1316_CR44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/15563651003596113","volume":"48","author":"R Witoonpanich","year":"2010","unstructured":"Witoonpanich R, Vichayanrat E, Tantisiriwit K, Wongtanate M, Sucharitchan N, Oranrigsupak P, Chuesuwan A, Nakarawat W, Tima A, Suwatcharangkoon S, et al. Survival analysis for respiratory failure in patients with food-borne botulism. Clin Toxicol (Phila). 2010;48:177\u201383. https:\/\/doi.org\/10.3109\/15563651003596113.","journal-title":"Clin Toxicol (Phila)"},{"key":"1316_CR45","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1093\/cid\/cix816","volume":"66","author":"PA Yu","year":"2017","unstructured":"Yu PA, Lin NH, Mahon BE, Sobel J, Yu Y, Mody RK, Gu W, Clements J, Kim HJ, Rao AK. Safety and improved clinical outcomes in patients treated with new equine-derived heptavalent botulinum antitoxin. Clin Infect Dis. 2017;66:S57\u201364. https:\/\/doi.org\/10.1093\/cid\/cix816.","journal-title":"Clin Infect Dis"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01316-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-025-01316-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01316-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:48:50Z","timestamp":1757310530000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-025-01316-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1316"],"URL":"https:\/\/doi.org\/10.1186\/s10020-025-01316-0","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental protocol was approved by the Animal Care and Use Committee at the Wake Forest University School of Medicine and elements were reviewed by the Animal Care and Use Review Office of the US Army Medical Research and Development Command. Animal studies were conducted according to the principles stated in the Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966. The views expressed in this manuscript are those of the author(s) and do not reflect the official policy of the Department of Army, Department of Defense, National Institutes of Health or the U.S. Government.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"270"}}